{"id":3870,"date":"2025-03-31T18:11:51","date_gmt":"2025-03-31T18:11:51","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/cyproterone-acetate-txt\/"},"modified":"2025-03-31T18:11:51","modified_gmt":"2025-03-31T18:11:51","slug":"cyproterone-acetate-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/cyproterone-acetate-txt\/","title":{"rendered":"Cyproterone acetate.txt"},"content":{"rendered":"

Cyproterone acetate<\/h1>\n

CLINICAL USE <\/H3>
\nControl of libido in severe hypersexuality and sexual deviation in adult maleManagement of patients with prostatic cancer (LHRH \u2018flare\u2019, palliative treatment)Hot flushes post orchidectomy

DOSE IN NORMAL RENAL FUNCTION <\/H3>Control of hypersexuality: 50 mg twice dailyProstatic cancer: 200\u2013300 mg\/day in 2\u20133 divided dosesHot flushes: 50\u2013150 mg daily in 1\u20133 divided doses

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :416.9<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Approx 96<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <1<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :10\u201330 <\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :32.1\u201356.7\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unknown dialysability. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsNone known

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>May cause drowsiness \u2013 increased CNS sensitivity in patients with renal impairmentCSM has advised that in view of the hepatotoxicity associated with long-term doses of 300 mg daily, the use of cyproterone acetate in prostatic cancer should be restricted to short courses, to cover testosterone \u2018flare\u2019 associated with gonadorelin analogues, treatment of hot flushes after orchidectomy or gonadorelin analogues, and for patients who have not responded to (or are intolerant of) other treatmentsDirect hepatic toxicity including jaundice, hepatitis and hepatic failure have been reported. Liver function tests should be performed before treatment and whenever symptoms suggestive of hepatotoxicity occur
    \n","protected":false},"excerpt":{"rendered":"

    Cyproterone acetate CLINICAL USE Control of libido in severe hypersexuality<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3870","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3870"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3870\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}